| Evolent Pathways | Febrile Neutropenic Risk | Emetogenic Risk | References | ||
|---|---|---|---|---|---|
| EXTREMITY/SUPERFICIAL TRUNK/HEAD & NECK/RETROPERITONEAL/INTRA-ABDOMINAL - UNRESECTABLE OR RECURRENT OR STAGE IV | |||||
Initial Therapy |
AD (doxorubicin and dacarbazine) |
High | High |
|
|
gemcitabine |
Low | Low |
|
||
doxorubicin |
High | High |
|
||
ifosfamide |
Low | Moderate |
|
||
Subsequent Therapy |
eribulin *for Liposarcoma* |
Low | Low |
|
|
Best Supportive Care or Clinical Trial |
|
||||
Initial Therapy
AD (doxorubicin and dacarbazine)
gemcitabine
doxorubicin
ifosfamide
Subsequent Therapy
eribulin *for Liposarcoma*
Best Supportive Care or Clinical Trial
| Regimen | Alternative | References | |||
|---|---|---|---|---|---|
| LOW VALUE REGIMENS (NON-PATHWAY) WITH SUPERIOR ALTERNATIVES | |||||
Subsequent Therapy |
** pembrolizumab ** cutaneous angiosarcoma, myxofibrosarcoma, UPS, cutaneous angiosarcoma and undifferentiated sarcomas |
Alternative: pazopanib |
|||
Subsequent Therapy |
** trabectedin ** all subtypes other than liposarcoma and leiomyosarcoma |
Alternative: doxorubicin |
|||
Subsequent Therapy
** pembrolizumab ** cutaneous angiosarcoma, myxofibrosarcoma, UPS, cutaneous angiosarcoma and undifferentiated sarcomas
Subsequent Therapy
** trabectedin ** all subtypes other than liposarcoma and leiomyosarcoma